Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)

Ascendis Pharma A has disclosed Non-Current Debt across 5 years of filings, most recently posting $448.5 million for Q4 2025.

• Non-Current Debt for Q4 2025 came in at $448.5 million, up 14.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $448.5 million (up 14.95% YoY), and the FY2025 annual result was $448.5 million, up 14.95% from the prior year.
• Non-Current Debt came in at $448.5 million for Q4 2025 at Ascendis Pharma A, up from $390.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $448.5 million in Q4 2025 to a low of $112.1 million in Q4 2021.
• The 5-year median for Non-Current Debt is $390.1 million (2024), against an average of $317.2 million.
• Across the five-year window, Non-Current Debt jumped 252.82% in 2022 and tumbled 39.32% in 2023, its largest moves.
• Ascendis Pharma A's Non-Current Debt stood at $112.1 million in 2021, then surged by 252.82% to $395.4 million in 2022, then sank by 39.32% to $239.9 million in 2023, then surged by 62.6% to $390.1 million in 2024, then rose by 14.95% to $448.5 million in 2025.
• The last three Non-Current Debt figures came in at $448.5 million (Q4 2025), $390.1 million (Q4 2024), and $239.9 million (Q4 2023), per Business Quant data.